Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLN-74809 in idiopathic pulmonary fibrosis
NCT05621252Phase 2Completed
- Sponsor
- Pliant Therapeutics
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PLN-74809 with Placebo (2 arms). Primary endpoint: Type 1 Collagen Deposition in Lungs Measured by 68Ga-CBP8 PET/MRI at 12 weeks. Started Jul 2022; status: completed.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05621252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621252.